Chronic Toxic Effects Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
25/03/2021
0:00
17:39
Interview with Douglas B. Johnson, MD, author of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
Mais episódios de "JAMA Oncology Author Interviews"
Não percas um episódio de “JAMA Oncology Author Interviews” e subscrevê-lo na aplicação GetPodcast.